Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Articles

---

December 6th 2019

Abstract Recap: Cost-Effectiveness and Budget Impact of Tildrakizumab for First-Line Treatment of Plaque Psoriasis

Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Latest Updated Articles

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: September 19th 2024 | Updated: November 21st 2024

Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes